Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Age-Related Macular Degeneration Clinical Trials

105 recruiting trials for Age-Related Macular Degeneration. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
105
Total Trials
105
Recruiting Now
11
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGNCT06203106

NYSCF Scientific Discovery Biobank

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate diverse disease research using cells from the body (such as skin or blood...

Sponsor: New York Stem Cell Foundation Research InstituteEnrolling: 100001 location
RECRUITINGNCT07084883

Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular...

The purpose of this study is to perform a pivotal trial of iPredict, an automated AI-based system for early diagnosis and prediction of late AMD in primary care and ophthalmology...

Sponsor: iHealthScreen IncEnrolling: 10761 location
RECRUITINGNCT03949972

The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)

In a monocentric, later multicentric prospective approach the FOrMe registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry) aims to generate a...

Sponsor: Prof. Dr. Paul BrinkkoetterEnrolling: 50012 locations
RECRUITINGNCT05438732

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with...

Sponsor: VisionCare, Inc.Enrolling: 12510 locations
RECRUITINGPhase 1 / Phase 2NCT05769153

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular...

Sponsor: Alcon ResearchEnrolling: 14020 locations
RECRUITINGNCT07178639

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery

The goal of this clinical trial is to learn which of the drugs bromfenac 0.09%, nepafenac 0.3% and diclofenac 0.1% has better efficacy in treatment and prevention of cystoid...

Sponsor: Nemocnice KolínEnrolling: 1501 location
RECRUITINGEarly Phase 1NCT07021027

Eggs and Age-related Macular Degeneration (EggsAMD) Study.

Age-related macular degeneration (AMD) is the primary cause of vision loss in people over the age of 55. Currently, no cure is available for individuals suffering from AMD. The...

Sponsor: Kathryn StarrEnrolling: 201 location
RECRUITINGNCT04591483

Stargardt-like Macular Dystrophy (STDG3) Secondary to Mutations in ELOVL4

Background: STDG3 is an inherited eye disease. Currently there is no treatment for STDG3. Past studies of STDG3 have largely looked at members of large families at a single time...

Sponsor: National Eye Institute (NEI)Enrolling: 251 location
RECRUITINGNCT06557369

A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

The proposed clinical investigation wants primary to validate the safety of the innovative light therapy approach and in second priority provide insight and confirmations on...

Sponsor: Oculox Technologies SAEnrolling: 301 location
RECRUITINGNCT05635266

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and...

Sponsor: Sanguine BiosciencesEnrolling: 200001 location
RECRUITINGNCT02617966

Rod and Cone Mediated Function in Retinal Disease

Background: Retinal diseases cause the loss of rod and cone photoreceptors. Symptoms include vision loss and night blindness. Researchers want to learn about rod and cone...

Sponsor: National Eye Institute (NEI)Enrolling: 5001 location
RECRUITINGPhase 3NCT05904028

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.

Sponsor: Jaeb Center for Health ResearchEnrolling: 60020 locations
RECRUITINGPhase 1NCT07230834

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop...

Sponsor: Regeneron PharmaceuticalsEnrolling: 544 locations
RECRUITINGPhase 2NCT06990269

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics...

Sponsor: ADARx Pharmaceuticals, Inc.Enrolling: 24017 locations
RECRUITINGNCT03752840

Village-Integrated Eye Worker Trial II

The vast majority of blindness is avoidable. The World Health Organization (WHO) estimates that 80% of cases of visual impairment could be prevented or reversed with early...

Sponsor: University of California, San FranciscoEnrolling: 602001 location
RECRUITINGPhase 1 / Phase 2NCT04225611

Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema

The main aim of the pilot study is to determine preliminary estimates of the safety, tolerability, and comfort of a dexamethasone-eluting therapeutic contact lens drug delivery...

Sponsor: Massachusetts Eye and Ear InfirmaryEnrolling: 61 location
RECRUITINGNCT02435940

Inherited Retinal Degenerative Disease Registry

The My Retina Tracker® Registry is sponsored by the Foundation Fighting Blindness and is for people affected by one of the rare inherited retinal degenerative diseases studied by...

Sponsor: Foundation Fighting BlindnessEnrolling: 200001 location
RECRUITINGNCT05913063

Direct Discrimination of Quantum States by the Human Eye

Age-related macular degeneration (AMD), is a debilitating eye disease that causes a loss of central vision. The prevalence of AMD increases exponentially with age and causes a...

Sponsor: Centre for Eye and Vision ResearchEnrolling: 501 location
RECRUITINGPhase 2 / Phase 3NCT04704921

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in...

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD)....

Sponsor: AbbVieEnrolling: 63020 locations
RECRUITINGNCT06439576

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular...

The Farseeing Study will explore long-term effectiveness, safety, and treatment patterns among patients being treated with faricimab in real-world, routine clinical practice in...

Sponsor: Hoffmann-La RocheEnrolling: 100020 locations
RECRUITINGNCT02026843

Analysis of Biomarkers From Patients With Chorioretinal Diseases

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases,...

Sponsor: Kyungpook National University HospitalEnrolling: 1001 location
RECRUITINGNCT02817997

International Registry for Patients With Castleman Disease

The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of...

Sponsor: University of PennsylvaniaEnrolling: 10001 location
RECRUITINGNCT06351670

Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and...

The goal of this prospective, multinational, multicenter observational study is to to predict conversion of early and intermediate AMD with functional vision to advanced AMD with...

Sponsor: Medical University of ViennaEnrolling: 5007 locations
RECRUITINGPhase 1NCT06132035

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed...

Sponsor: Caregen Co. Ltd.Enrolling: 457 locations
RECRUITINGNCT06491615

National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and...

Background: The eyeGENE (Registered Trademark) program is a research resource for inherited eye conditions which includes genotypic and phenotypic data, imaging, and a...

Sponsor: National Eye Institute (NEI)Enrolling: 10002 locations
RECRUITINGEarly Phase 1NCT07053358

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

The goal of this study is to evaluate the safety and efficacy of LX111 treatment of nAMD. This study will enroll subjects aged ≥ 50 vears old to receive a single unilateral...

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEnrolling: 101 location
RECRUITINGPhase 4NCT06970665

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related...

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their vision over time. AMD damages the macula, which is in the middle of the retina - the...

Sponsor: Astellas Pharma IncEnrolling: 2016 locations
RECRUITINGPhase 3NCT05407636

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD...

Sponsor: AbbVieEnrolling: 66020 locations
RECRUITINGNCT01432847

Cell Collection to Study Eye Diseases

Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light...

Sponsor: National Eye Institute (NEI)Enrolling: 9301 location
RECRUITINGNCT07425574

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Macular dystrophies are a group of inherited eye conditions that affect the macula. The macula is in the center of the retina, the light sensitive part at the back of the eye. In...

Sponsor: Astellas Pharma Global Development, Inc.Enrolling: 901 location
RECRUITINGNCT05355415

Adaptive Optics Imaging of Outer Retinal Diseases

The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor,...

Sponsor: Food and Drug Administration (FDA)Enrolling: 1002 locations
RECRUITINGNCT05465252

Effect of Omega-3 Fatty Acid Supplementation on Dry-AMD Progression

This randomized, double-blind, placebo-controlled study aims to evaluate the effect of krill oil supplementation in patients with dry age-related macular degeneration (AMD)....

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineEnrolling: 241 location
RECRUITINGNCT06346600

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular...

Sponsor: Skyline TherapeuticsEnrolling: 8310 locations
RECRUITINGPhase 1 / Phase 2NCT07002398

Safety and Preliminary Efficacy of VG801 in Patients With ABCA4 Mutation-associated Retinal Dystrophy (Stargardt...

This is a single-arm, open-label, non-randomized, single dose-escalation, first-in-human (FIH) clinical trial to evaluate the safety and preliminary efficacy of VG801 for...

Sponsor: VeonGen Therapeutics GmbHEnrolling: 151 location
RECRUITINGEarly Phase 1NCT07063251

An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease

Stargardt disease type 1 (STGD1) is a rare genetic eye condition that causes progressive vision loss, often beginning in childhood or adolescence. It is the most common form of...

Sponsor: HuidaGene Therapeutics Co., Ltd.Enrolling: 61 location
RECRUITINGNCT06271330

Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.

Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal...

Sponsor: Nantes University HospitalEnrolling: 1001 location
RECRUITINGNCT04129021

High Resolution, High-speed Multimodal Ophthalmic Imaging

Knowledge of the pathogenesis of ocular conditions, a leading cause of blindness, has benefited greatly from recent advances in ophthalmic imaging. However, current clinical...

Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsEnrolling: 12001 location
RECRUITINGPhase 1NCT06961370

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of...

The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or...

Sponsor: Hoffmann-La RocheEnrolling: 13216 locations
RECRUITINGNCT00874783

Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases

Human fibroblasts and possibly other human somatic cells may be reprogrammed into induced pluripotent stem (iPS) cells by the forced expression of transcription factors (1-5). The...

Sponsor: Hadassah Medical OrganizationEnrolling: 1201 location
RECRUITINGPhase 1 / Phase 2NCT06141460

Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

A Phase I/IIa, Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of Single Subretinal Injection of RRG001 in Subjects With Neovascular Age-related...

Sponsor: Shanghai Refreshgene Technology Co., Ltd.Enrolling: 481 location
RECRUITINGPhase 1 / Phase 2NCT07185256

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD)...

The goal of this clinical trial is to learn if drug OPGx-BEST1 works to treat BVMD and ARB Bestrophinopathy. It will also learn about the safety of drug OPGx-BEST1. The main...

Sponsor: Opus Genetics, IncEnrolling: 104 locations
RECRUITINGPhase 2NCT07215390

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability,...

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with...

Sponsor: Apellis Pharmaceuticals, Inc.Enrolling: 24020 locations
RECRUITINGPhase 1 / Phase 2NCT07439887

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients...

A Phase 1/2, open-label, non-randomized, dose-escalation study, where a minimum of 9 and a maximum of 18 eligible patients with Stargardt Disease will be enrolled sequentially in...

Sponsor: Ray Therapeutics, Inc.Enrolling: 182 locations
RECRUITINGNCT07235527

Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular...

In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.

Sponsor: Saglik Bilimleri UniversitesiEnrolling: 541 location
RECRUITINGNCT06435000

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic...

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene This is a...

Sponsor: Splice BioEnrolling: 7520 locations
RECRUITINGPhase 1 / Phase 2NCT06660667

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

This is a Phase 1/Phase 2 multicenter study to evaluate the safety and efficacy of a one-time single-eye intravitreal dose of SAR402663 in participants with neovascular...

Sponsor: SanofiEnrolling: 6618 locations
RECRUITINGNCT05932069

Active AMD Study to Improve Function in Veterans

Age Related Macular Degeneration (AMD) is the leading cause of vision loss among Veterans aged 50 years and older. AMD also adversely affects mortality, physical and cognitive...

Sponsor: VA Office of Research and DevelopmentEnrolling: 701 location
RECRUITINGNCT04697095

Survival of Monocytes Collected From Patients With Atrophic AMD in Retinal Pigmented Epithelium Explants

Age-related macular degeneration (AMD) affects 2 million people in France and is the main cause of irreversible blindness in France. All patients initially have an early form of...

Sponsor: Hospices Civils de LyonEnrolling: 802 locations
RECRUITINGNCT06596408

Evaluation of Retinal Vascular Density in High Myopia Without Pathological Myopic Maculopathy Using OCTA .

Study aiming to evaluate Macular Vascular Density in High Myopes without pathological myopic maculopathy in outpatient clinic in Sohag teaching hospital using OCTA .

Sponsor: Sohag UniversityEnrolling: 501 location
RECRUITINGPhase 2NCT06659549

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to...

Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a...

Sponsor: Galimedix Therapeutics IncEnrolling: 11014 locations

Showing 50 of 105 trials.Search all Age-Related Macular Degeneration trials